等待开盘 11-19 09:30:00 美东时间
-0.007
-0.87%
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 29.41 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $171.000 thousan...
11-12 20:17
Cardiff Oncology announced positive Phase 2 trial results for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC), with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus 11 months in the control arm. All patients in the 30 mg arm have exceeded 21 months on treatment. The company plans to initiate a registrational Phase 3 trial in Q1 2027, targeting first-line RAS-mutated mCRC. Cardiff also reported $33...
11-12 12:00
Cardiff Oncology announced its participation in the UBS Global Biopharma Conference on November 16-17, 2026. CEO Mani Mohindru, PhD, will host a Fireside Chat on November 16 at 2:40 PM GMT. Investors can register and access the live webcast via the company's website. Cardiff Oncology focuses on PLK1 inhibition for cancer treatments, with its lead asset, onvansertib, in Phase 2 trials for RAS-mutated mCRC. More information is available at https://...
11-03 12:00
Cardiff Oncology ( ($CRDF) ) has shared an announcement. Cardiff Oncology expan...
10-28 04:58
Cardiff Oncology appoints Leila Alland, MD, as interim Chief Medical Officer, replacing Roger Sidhu, MD. Dr. Alland brings extensive oncology drug development experience, having led programs at多家生物制药公司, including AstraZeneca, Bristol Myers Squibb, and Novartis. Her expertise will guide Cardiff's Phase 3 study for onvansertib, a PLK1 inhibitor targeting RAS-mutated cancers, as the company prepares to initiate its registrational Phase 3 trial in ea...
10-27 20:05
Cardiff Oncology ( ($CRDF) ) just unveiled an update. On October 22, 2026, Card...
10-23 05:04
Cardiff Oncology announced that the FDA granted Orphan Drug Designation to onvansertib for treating chronic myelomonocytic leukemia (CMML). Onvansertib, a PLK1 inhibitor, showed promise in early trials, with 40% of patients experiencing clinical benefits. Orphan Drug Designation offers benefits like tax credits and market exclusivity, supporting the development of therapies for rare diseases. Onvansertib is also being tested in other cancers, inc...
10-21 20:05
今日重点评级关注:HC Wainwright & Co.:上调Cardiff Oncology评级至"买入",目标价9美元;古根海姆:维持Inventiva"买入"评级,目标价从11美元升至14美元
09-16 16:10
HC Wainwright & Co. analyst Robert Burns upgrades Cardiff Oncology (NASDAQ:CRDF) from Neutral to Buy and announces $9 price target.
09-15 18:28